公开(公告)号：US20230193260A1

公开(公告)日：2023-06-22

申请号：US17815493

申请日：2022-07-27

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. OLSON ,  Angela M. Cacace ,  Jere E. Meredith, JR. ,  Nino Devidze ,  James K. Loy ,  Carl J. Baldick ,  Annapurna Pendri ,  Ivar M. McDonald ,  Peter Hagedorn ,  Marianne Lerbech Jensen

IPC: C12N15/113

CPC classification number: C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/351 ,  C12N2310/3231

Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

公开(公告)号：US11447775B2

公开(公告)日：2022-09-20

申请号：US16961624

申请日：2019-01-11

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. Olson ,  Angela M. Cacace ,  Jere E. Meredith, Jr. ,  Nino Devidze ,  James K. Loy ,  Carl J. Baldick ,  Annapurna Pendri ,  Ivar M. McDonald ,  Peter Hagedorn ,  Marianne Lerbech Jensen

IPC: C07H21/04 ,  C12N15/113

Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

公开(公告)号：US12162848B2

公开(公告)日：2024-12-10

申请号：US18161184

申请日：2023-01-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Haibo Liu ,  Laura Akullian D'Agostino ,  Shoshana L. Posy ,  Annapurna Pendri ,  Swanee E. Jacutin-Porte

IPC: C07D285/06 ,  A61K45/06 ,  A61P35/00 ,  C07D417/10 ,  C07D417/12

Abstract: Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PNPT2 inhibition.

公开(公告)号：US09034882B2

公开(公告)日：2015-05-19

申请号：US13782198

申请日：2013-03-01

Applicant: Bristol-Myers Squibb Company

Inventor： Annapurna Pendri ,  David R. Langley ,  Samuel Gerritz ,  Guo Li ,  Weixu Zhai ,  Stanley D'Andrea ,  Manoj Patel ,  B. Narasimhulu Naidu ,  Kevin Peese ,  Zhongyu Wang

IPC: A01N43/90 ,  A61K31/519 ,  C07D487/00 ,  C07D487/04 ,  C07D498/08 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D498/08 ,  C07D519/00

Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

公开(公告)号：US20130231331A1

公开(公告)日：2013-09-05

申请号：US13782198

申请日：2013-03-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Annapurna Pendri ,  David R. Langley ,  Samuel Gerritz ,  Guo Li ,  Weixu Zhai ,  Stanley D'Andrea ,  Manoj Patel ,  B. Narasimhulu Naidu ,  Kevin Peese ,  Zhongyu Wang

IPC: C07D487/04 ,  C07D498/08

CPC classification number: C07D487/04 ,  C07D498/08 ,  C07D519/00

Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

Abstract translation: 本公开一般涉及式I化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。 本公开提供了HIV的新型抑制剂，含有这些化合物的药物组合物，以及使用这些化合物治疗HIV感染的方法。

公开(公告)号：US11359197B2

公开(公告)日：2022-06-14

申请号：US17165841

申请日：2021-02-02

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. Olson ,  Angela M. Cacace ,  Jere E. Meredith, Jr. ,  Nino Devidze ,  James K. Loy ,  Carl J. Baldick ,  Annapurna Pendri ,  Ivar M. McDonald ,  Peter Hagedorn ,  Marianne Lerbech Jensen

IPC: C12N15/113

Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

公开(公告)号：US12180478B2

公开(公告)日：2024-12-31

申请号：US17815493

申请日：2022-07-27

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. Olson ,  Angela M. Cacace ,  Jere E. Meredith, Jr. ,  Nino Devidze ,  James K. Loy ,  Carl J. Baldick ,  Annapurna Pendri ,  Ivar M. McDonald ,  Peter Hagedorn ,  Marianne Lerbech Jensen

IPC: C07H21/04 ,  C12N15/113

Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

公开(公告)号：US20230322695A1

公开(公告)日：2023-10-12

申请号：US18161184

申请日：2023-01-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Haibo Liu ,  Laura Akullian D′Agostino ,  Shoshana L. Posy ,  Annapurna Pendri ,  Swanee E. Jacutin-Porte

IPC: C07D285/06 ,  A61K45/06 ,  A61P35/00 ,  C07D417/12 ,  C07D417/10

CPC classification number: C07D285/06 ,  A61K45/06 ,  A61P35/00 ,  C07D417/10 ,  C07D417/12

Abstract: Disclosed are compounds of Formula (I)





pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PNPT2 inhibition.

公开(公告)号：US20160257645A1

公开(公告)日：2016-09-08

申请号：US15031352

申请日：2014-10-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Annapurna Pendri ,  Guo Li ,  John A. Bender ,  Zhong Yang ,  Alan Xiangdong Wang ,  Brett R. Beno ,  Robert A. Fridell ,  Makonen Belema ,  Nicholas A. Meanwell ,  Robert G. Gentles

IPC: C07C311/58 ,  C07D317/66 ,  C07D409/12 ,  C07D405/12 ,  C07D317/46 ,  C07D407/12 ,  C07D271/06 ,  C07D307/38 ,  C07D333/18 ,  C07D231/12 ,  C07D333/54 ,  C07D209/10 ,  C07D333/28 ,  C07D261/08 ,  C07D215/08 ,  C07D209/08 ,  C07D277/82 ,  C07D495/04 ,  C07D491/08 ,  C07D205/04 ,  C07D401/04 ,  C07D213/56 ,  C07D249/08 ,  C07D265/36

CPC classification number: C07C311/58 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07D205/04 ,  C07D209/08 ,  C07D209/10 ,  C07D213/56 ,  C07D215/08 ,  C07D231/12 ,  C07D249/08 ,  C07D261/08 ,  C07D265/36 ,  C07D271/06 ,  C07D277/82 ,  C07D307/38 ,  C07D317/46 ,  C07D317/66 ,  C07D333/18 ,  C07D333/28 ,  C07D333/54 ,  C07D401/04 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D491/08 ,  C07D495/04

Abstract: Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: Formula: (I)

Abstract translation: 阐述了具有抗HIV活性的式I化合物，包括药物组合物和使用这些化合物治疗人类免疫缺陷病毒（HIV）感染的方法：式（I）